BMO Capital Markets Issues Pessimistic Forecast for Doximity (NYSE:DOCS) Stock Price

Doximity (NYSE:DOCS) had its price target reduced by equities researchers at BMO Capital Markets from $25.00 to $20.00 in a note issued to investors on Thursday, MarketBeat.com reports. The brokerage currently has a “market perform” rating on the stock. BMO Capital Markets’ price objective points to a potential upside of 5.68% from the stock’s current price.

A number of other brokerages have also weighed in on DOCS. JPMorgan Chase & Co. cut their target price on shares of Doximity from $40.00 to $33.00 and set a “neutral” rating on the stock in a research report on Friday, February 20th. Loop Capital set a $31.00 target price on shares of Doximity in a research report on Tuesday, March 17th. Robert W. Baird restated a “neutral” rating and issued a $18.00 target price (down from $40.00) on shares of Doximity in a research report on Thursday. Bank of America cut their target price on shares of Doximity from $56.00 to $47.00 and set a “buy” rating on the stock in a research report on Thursday, April 16th. Finally, The Goldman Sachs Group cut their target price on shares of Doximity from $34.00 to $28.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and fourteen have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $30.62.

Doximity Price Performance

Shares of Doximity stock opened at $18.93 on Thursday. Doximity has a fifty-two week low of $17.15 and a fifty-two week high of $76.51. The firm has a market capitalization of $3.50 billion, a price-to-earnings ratio of 19.12, a P/E/G ratio of 1.28 and a beta of 1.36. The company has a 50 day moving average of $23.94.

Doximity declared that its board has initiated a stock repurchase plan on Thursday, February 5th that permits the company to repurchase $500.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 8% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at Doximity

In related news, Director Kira Scherer Wampler sold 9,000 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $26.06, for a total value of $234,540.00. Following the transaction, the director owned 19,839 shares in the company, valued at $517,004.34. The trade was a 31.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Siddharth Sitaram sold 2,427 shares of the business’s stock in a transaction on Friday, April 10th. The shares were sold at an average price of $21.09, for a total transaction of $51,185.43. Following the completion of the transaction, the insider owned 86,705 shares in the company, valued at approximately $1,828,608.45. The trade was a 2.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 18,055 shares of company stock worth $456,061. 31.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Doximity

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Doximity by 4.1% during the fourth quarter. Vanguard Group Inc. now owns 13,285,485 shares of the company’s stock valued at $588,281,000 after purchasing an additional 518,916 shares during the period. Aubrey Capital Management Ltd acquired a new position in shares of Doximity during the third quarter valued at about $4,572,000. UBS Group AG raised its holdings in shares of Doximity by 26.5% during the fourth quarter. UBS Group AG now owns 680,260 shares of the company’s stock valued at $30,122,000 after purchasing an additional 142,408 shares during the period. Blair William & Co. IL raised its holdings in shares of Doximity by 1,990.7% during the third quarter. Blair William & Co. IL now owns 362,740 shares of the company’s stock valued at $26,534,000 after purchasing an additional 345,390 shares during the period. Finally, William Blair Investment Management LLC raised its holdings in shares of Doximity by 11.7% during the third quarter. William Blair Investment Management LLC now owns 5,829,169 shares of the company’s stock valued at $426,404,000 after purchasing an additional 609,775 shares during the period. Institutional investors and hedge funds own 87.19% of the company’s stock.

Key Doximity News

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity said revenue still grew year over year, and its earnings call highlighted strong engagement from AI tool adoption, suggesting the platform is gaining traction with physicians. Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down
• Positive Sentiment: Doximity announced a partnership with Aledade to bring clinical AI tools into value-based care workflows, which could support longer-term adoption and monetization. DOCS Teams Up With Aledade to Bring Clinical AI to Value-Based Care
• Neutral Sentiment: Several articles noted the stock has become technically oversold after a sharp selloff, which could set up a bounce if sentiment improves. Down 25.7% in 4 Weeks, Here’s Why Doximity (DOCS) Looks Ripe for a Turnaround
• Negative Sentiment: Doximity missed quarterly earnings estimates and issued fiscal 2027 revenue guidance below Wall Street expectations, raising concerns that growth is slowing. Doximity, Inc. (DOCS) Q4 2026 Earnings Call Transcript
• Negative Sentiment: Analysts turned more cautious, with multiple firms cutting price targets or downgrading the stock, including Baird, Wells Fargo, BTIG, JPMorgan, Mizuho, BMO, Needham and Truist. DOCS vs. HIMS: Which Stock Is the Better Value Option?
• Negative Sentiment: Investor caution also increased after insider selling was disclosed, even though it was tied to a pre-arranged 10b5-1 plan and tax withholding. Doximity (NYSE:DOCS) Insider Siddharth Sitaram Sells 2,309 Shares

Doximity Company Profile

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.